A new study confirms that plasma p-tau181 levels can identify subjective cognitive decline (SCD) as a distinct early stage of ...

A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and ...

The a-secretase cleavage site lies within the amyloid-beta peptide associated with Alzheimer plaques. Therefore, an increase in asecretase activity has been found to be associated with a decrease ...

A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to scientists. By engineering human ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

RIKEN researchers have demonstrated the protective effects of a specific genetic mutation against Alzheimer's disease in ...

Learn about the impact of Alzheimer's family history on brain resilience and memory function. Your family tree may shape your ...

An experimental drug that clears amyloid beta from the brain cut the risk of developing Alzheimer’s by 50% among a group of 22 people with genetic mutations that all but guarantee they would ...

Promis Neurosciences Inc. recently presented the rational design of an Alzheimer’s disease (AD) vaccine candidate maximizing the selective targeting of toxic amyloid-β oligomers.

The following is a summary of “Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease,” ...

MONDAY, March 24, 2025 (HealthDay News) -- The best evidence yet that cutting-edge Alzheimer’s disease drugs might indeed ward off the degenerative brain disease has emerged from a small-scale ...